Curis Inc. (CRIS), a biotechnology company developing novel therapies for slowing or preventing the progression of cancer and prolonging life, has several important clinical trial milestones lined up for the end of this year.
The company's lead drug candidate is Emavusertib, a first-in class IRAK4 inhibitor in phase I/II clinical studies in leukemia and lymphoma, dubbed TakeAim Leukemia and TakeAim Lymphoma.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.